WealthPlan Investment Management LLC Lowers Holdings in Amgen Inc. $AMGN

WealthPlan Investment Management LLC trimmed its holdings in Amgen Inc. (NASDAQ:AMGN) by 39.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 23,253 shares of the medical research company’s stock after selling 14,878 shares during the period. WealthPlan Investment Management LLC’s holdings in Amgen were worth $7,611,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Dogwood Wealth Management LLC raised its position in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after acquiring an additional 55 shares during the period. Anfield Capital Management LLC raised its position in shares of Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after acquiring an additional 70 shares during the period. Board of the Pension Protection Fund acquired a new position in shares of Amgen in the fourth quarter worth about $26,000. Manning & Napier Advisors LLC raised its position in shares of Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after acquiring an additional 32 shares during the period. Finally, Olistico Wealth LLC acquired a new position in shares of Amgen in the fourth quarter worth about $33,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on AMGN shares. Wall Street Zen downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Piper Sandler decreased their price objective on shares of Amgen from $432.00 to $427.00 and set an “overweight” rating for the company in a research report on Thursday. Guggenheim decreased their price objective on shares of Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a research report on Monday, May 4th. Citigroup upped their price objective on shares of Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Finally, Royal Bank Of Canada upped their price objective on shares of Amgen from $360.00 to $370.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Amgen has an average rating of “Hold” and a consensus target price of $356.15.

Amgen Stock Down 3.0%

AMGN opened at $326.31 on Friday. Amgen Inc. has a twelve month low of $267.73 and a twelve month high of $391.29. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The company has a 50-day moving average price of $349.17 and a 200 day moving average price of $342.99. The company has a market cap of $176.10 billion, a PE ratio of 22.71, a price-to-earnings-growth ratio of 3.28 and a beta of 0.44.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the prior year, the firm earned $4.90 EPS. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Sell-side analysts expect that Amgen Inc. will post 22.37 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 3.1%. Amgen’s dividend payout ratio is presently 70.15%.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.